Circulation.:AHA 右心衰竭的评估和管理科学声明:应用利尿剂重要

2018-04-24 佚名 中国循环杂志

近期,美国心脏协会(AHA)发布《右心衰竭的评估和管理科学声明》,对右心衰竭的病因、流行病学、病理生理学以及急慢性右心衰竭的管理进行了论述。

近期,美国心脏协会(AHA)发布《右心衰竭的评估和管理科学声明》,对右心衰竭的病因、流行病学、病理生理学以及急慢性右心衰竭的管理进行了论述。

1 右心衰竭是由右心室扩张和功能障碍引起相应体征和症状的临床综合征。其病因包括原发性心肌病、右心缺血和梗死、肺高血压、先天性心脏病和瓣膜病等等。

2 与左心室相比,右心室有不同的胚胎起源,在生理功能和解剖结构上存在不同,这解释了右心室对后负荷增加的敏感性。

3 右心衰竭常常与左心衰竭相关,有生存预测价值。

4 多种影像学成像模式用于评估右心室功能已经得到验证;然而,目前磁共振成像是测量体积、质量和收缩功能的金标准。

5 容量管理对急性右心衰竭的治疗至关重要,因为它会影响负荷情况、右心室功能、全身充血,但最重要的是心室相互依赖性,这会影响左心室充盈、每搏输出量和心输出量。

6 慢性右心衰竭管理的基石是口服利尿剂进行容量管理。其他治疗主要针对右心衰竭的病因,神经激素拮抗剂包括ACEI、β受体阻滞剂和盐皮质激素拮抗剂可能有益。

7 肺高血压的常常导致右心衰竭。肺血管扩张剂如磷酸二酯酶-5抑制剂、内皮素受体拮抗剂和前列环素类似物可为肺高血压患者带生存获益。

8 急性右心衰竭患者早期考虑机械循环支持很重要,这有助于右心室功能的恢复。

原始出处:
Konstam MA, Kiernan MS, Bernstein D, et al.Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association.Circulation. 2018 Apr 12. doi: 10.1161/CIR.0000000000000560. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687939, encodeId=02c7168e93911, content=<a href='/topic/show?id=eb1c3864644' target=_blank style='color:#2F92EE;'>#右心衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38646, encryptionId=eb1c3864644, topicName=右心衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3cb428423060, createdName=12498761m65暂无昵称, createdTime=Wed Nov 28 20:37:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937706, encodeId=61cc193e70634, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Oct 28 09:37:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079041, encodeId=5edc20e90418f, content=<a href='/topic/show?id=f5e55194e2b' target=_blank style='color:#2F92EE;'>#心衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51947, encryptionId=f5e55194e2b, topicName=心衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Jun 25 07:37:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267804, encodeId=812e126e8044d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Apr 26 05:37:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271944, encodeId=0b7b12e194414, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Thu Apr 26 05:37:00 CST 2018, time=2018-04-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1687939, encodeId=02c7168e93911, content=<a href='/topic/show?id=eb1c3864644' target=_blank style='color:#2F92EE;'>#右心衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38646, encryptionId=eb1c3864644, topicName=右心衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3cb428423060, createdName=12498761m65暂无昵称, createdTime=Wed Nov 28 20:37:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937706, encodeId=61cc193e70634, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Oct 28 09:37:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079041, encodeId=5edc20e90418f, content=<a href='/topic/show?id=f5e55194e2b' target=_blank style='color:#2F92EE;'>#心衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51947, encryptionId=f5e55194e2b, topicName=心衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Jun 25 07:37:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267804, encodeId=812e126e8044d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Apr 26 05:37:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271944, encodeId=0b7b12e194414, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Thu Apr 26 05:37:00 CST 2018, time=2018-04-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1687939, encodeId=02c7168e93911, content=<a href='/topic/show?id=eb1c3864644' target=_blank style='color:#2F92EE;'>#右心衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38646, encryptionId=eb1c3864644, topicName=右心衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3cb428423060, createdName=12498761m65暂无昵称, createdTime=Wed Nov 28 20:37:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937706, encodeId=61cc193e70634, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Oct 28 09:37:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079041, encodeId=5edc20e90418f, content=<a href='/topic/show?id=f5e55194e2b' target=_blank style='color:#2F92EE;'>#心衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51947, encryptionId=f5e55194e2b, topicName=心衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Jun 25 07:37:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267804, encodeId=812e126e8044d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Apr 26 05:37:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271944, encodeId=0b7b12e194414, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Thu Apr 26 05:37:00 CST 2018, time=2018-04-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1687939, encodeId=02c7168e93911, content=<a href='/topic/show?id=eb1c3864644' target=_blank style='color:#2F92EE;'>#右心衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38646, encryptionId=eb1c3864644, topicName=右心衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3cb428423060, createdName=12498761m65暂无昵称, createdTime=Wed Nov 28 20:37:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937706, encodeId=61cc193e70634, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Oct 28 09:37:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079041, encodeId=5edc20e90418f, content=<a href='/topic/show?id=f5e55194e2b' target=_blank style='color:#2F92EE;'>#心衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51947, encryptionId=f5e55194e2b, topicName=心衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Jun 25 07:37:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267804, encodeId=812e126e8044d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Apr 26 05:37:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271944, encodeId=0b7b12e194414, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Thu Apr 26 05:37:00 CST 2018, time=2018-04-26, status=1, ipAttribution=)]
    2018-04-26 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=1687939, encodeId=02c7168e93911, content=<a href='/topic/show?id=eb1c3864644' target=_blank style='color:#2F92EE;'>#右心衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38646, encryptionId=eb1c3864644, topicName=右心衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3cb428423060, createdName=12498761m65暂无昵称, createdTime=Wed Nov 28 20:37:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937706, encodeId=61cc193e70634, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Oct 28 09:37:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079041, encodeId=5edc20e90418f, content=<a href='/topic/show?id=f5e55194e2b' target=_blank style='color:#2F92EE;'>#心衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51947, encryptionId=f5e55194e2b, topicName=心衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Jun 25 07:37:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267804, encodeId=812e126e8044d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Apr 26 05:37:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271944, encodeId=0b7b12e194414, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Thu Apr 26 05:37:00 CST 2018, time=2018-04-26, status=1, ipAttribution=)]

相关资讯

2017AHA/ASA关于"无症状脑血管病"的科学声明

2017年2月AHA联合ASA共同在Stroke上发布了无症状脑血管病的卒中预防科学声明,现将推荐意见摘录如下。

Eur Heart J:多学科讨论:ACC/AHA极高风险标准分辨心血管病复发的能力如何?

临床上表现动脉粥样硬化性动脉疾病的患者一般被认为复发性心血管事件(MACE)风险高。2017年发表在《Eur Heart J》的一项由荷兰、美国、法国和英国科学家进行的研究,考察了目前ACC/AHA极高风险标准的分辨能力,并识别心血管病复发高风险患者的极高风险因素。请看本期多学科讨论组临床药师各抒己见为您梳理本文看点——

Circulation:AHA有关心血管病与卒中的统计数据之2018更新

近日,美国心脏协会(AHA)发布了有关心血管病和卒中的统计数据,其更新要点如下:

AHA公布2017年心血管病研究十大进展:脑卒中和高血压诊疗有重大变化

2月7日,美国心脏协会(AHA)官网公布了2017年心血管病研究十大进展,具体如下。

JAMA:美国糖尿病协会不同意ACC/AHA高血压指南:降压靶标为130/80有过度治疗之嫌

医学这门学科很年轻,因此有很多临床问题,不同学术组织思考的角度或对循证医学证据理解不同时,有时候就会“掐起架”来。

ISC2018:AHA主席呼吁从影响政策、系统和环境变化,来共同抗击卒中!

美国当地时间1月24日,2018年国际卒中大会(International Stroke Conference)在美国加利福尼亚州洛杉矶会议中心隆重开幕。来自世界各地卒中领域的4500余名同道共聚一堂,共商卒中防治大计。